Search Results

FDA Grants Profounda Orphan Drug Designation Approval for treatment of Treatment of Invasive Candidiasis with Miltefosine

Profounda, Inc. (“Profounda”) announced today that it has received the US Food and Drug Administration’s Orphan Drug Designation Approval for the use of miltefosine to treat Invasive Candidiasis with Miltefosine. Profounda licensed miltefosine (Impavido®) from Knight Therapeutics (TSX: GUD) Inc in 2013 for Leishmaniasis.

November 8, 2021

·

3 min read

Profounda Launches Rhinase Baby Lubricating Nasal Drops

Profounda announced today that Rhinase Baby Lubricating Nasal Drops is now available in the United States through Rhinase.com and Amazon.com as well as on retail shelves at Kinney Drugs. Patients can also ask their Pharmacists to order Rhinase products directly from Profounda or Cardinal Health.

January 23, 2018

·

2 min read

FDA Grants Profounda Orphan Drug Designation For Treatment Of Granulomatous Amebic Encephalitis (GAE) With Miltefosine

June 28, 2017

·

3 min read

FDA Orphan Drug Designation Granted To Profounda For The Treatment Of Acanthamoeba Keratitis With Miltefosine

December 19, 2016

·

3 min read

Profounda Receives FDA Orphan-Drug Designation For The Treatment Of Primary Amebic Meningoencephalitis (PAM) With Miltefosine

December 19, 2016

·

3 min read

Orlando Patient Survives Primary Amebic Meningoencephalitis (PAM) Using Profounda’s Drug Impavido (Miltefosine)

August 24, 2016

·

5 min read

Profounda, Inc. Launches Impavido (miltefosine), The First And Only Oral Rx Treatment For Visceral, Mucosal And Cutaneous Leishmaniasis, In The United States

March 22, 2016

·

5 min read

Profounda, Inc. Launches Second Product This Year, Rhinase, The Only Non-Prescription, Wetting-Agent Based Nasal Moisturizer That Will Help People With Nasal Dryness Associated With Allergies, Low Humidity, Stuffy Nose And Nosebleeds

July 19, 2016

·

2 min read

iCAD Announces Compelling Data Supporting Launch of First and Only Commercially Available Technology to Provide Short-Term Breast Cancer Risk Assessment

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling data supporting ProFound AI™ Risk was published in the peer-reviewed journal, Radiology.

September 15, 2020

·

9 min read

Pharm Country

ProFound AI™ Risk Receives CE Mark in Europe

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced ProFound AI™ Risk received a CE Mark in Europe

July 15, 2020

·

8 min read